THE TUMOR IMMUNE MICROENVIRONMENT AS A KEY DETERMINANT OF DISEASE PROGRESSION AND THERAPEUTIC RESPONSE IN HPV-ASSOCIATED CERVICAL CANCER
Keywords:
cervical cancer; HPV; tumor immune microenvironment; immune evasion.Abstract
This thesis synthesizes current concepts of HPV-driven immune remodeling across disease stages, highlights TIME features associated with progression and outcome, and discusses actionable translational strategies—including biomarker-guided immunotherapy combinations, microenvironment reprogramming, and multi-omics profiling—to improve responses and durability of control.
Downloads
References
1. Colombo N., Dubot C., Lorusso D., et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer // New England Journal of Medicine. – 2021. – Vol. 385, No. 20. – P. 1856–1867. – DOI: 10.1056/NEJMoa2112435. PubMed
2. Tewari K.S., Monk B.J., Vergote I., et al. Survival with Cemiplimab in Recurrent Cervical Cancer // New England Journal of Medicine. – 2022. – Vol. 386, No. 6. – P. 544–555. – DOI: 10.1056/NEJMoa2112187. PubMed
3. Manzo-Merino J., Del-Toro-Arreola S., Rocha-Zavaleta L., et al. Immunology of Cervical Cancer // Revista de Investigacion Clinica. – 2020. – Vol. 72, No. 4. – P. 188–197. – DOI: 10.24875/RIC.20000057. PubMed
4. Zhou X., An R., Li X., et al. Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review) // Oncology Letters. – 2026. – Vol. 31, No. 1. – Art. 22. – DOI: 10.3892/ol.2025.15375.
